cutaneous cGVHD. Graft-versus-host reaction or disease
Conditions
Interventions
Imatinib: 100 mg Imatinib Mesylate daily for the first month, 200 mg daily for the second and third months, and 400 mg daily for the next three months.
Treatment - Drugs
Imatinib: 100 mg Imatinib Mesylate daily for the first month, 200 mg daily for the second and third months, and 400 mg daily for the next three months
Sponsors
Hematology-Oncology and SCT Research Center
Eligibility
Sex/Gender
All
Age
16 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria 1- The patient shall undergo allogen bone marrow transplantation and have clinical and pathological cutaneous CGVHD criteria. 2- Patient’s cutaneous signs are not improved by taking corticosteroids with doses of 0.5 mg/kg at least for 3 months and cyclosporine. 3- The cutaneous signs shall be active. 4- The patient shall be aged between 16 to 60 years old. Exclusion Criteria 1- Pregnancy 2- Having a history of taking Rituximab.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The extent of cutaneous involvment. Timepoint: At the start of treatment and in the end of 6 month. Method of measurement: Skin examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Extent of skin involvement in pathology. Timepoint: At the start of treatment and in the end of 6 month. Method of measurement: Severity of involvement in pathology.;Side effect frequency. Timepoint: Every month after treatment up to 6 months. Method of measurement: Examination and fallowing treatment. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarjan Mehri
Hematology-Oncology and SCT Research Center
Outcome results
None listed